Latest news with #ThibautduFayet
Yahoo
4 days ago
- Business
- Yahoo
PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing
LYON, France, June 05, 2025--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ("Tribunal des activités économiques de Lyon") decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit View source version on Contacts PHAXIAM Thibaut du Fayet CEO+33 4 78 74 44 38investors@ NewCap Mathilde Bohin / Dušan Orešanský Investor RelationsArthur RouilléMedia Relations+33 1 44 71 94 94phaxiam@
Yahoo
14-03-2025
- Business
- Yahoo
PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure
LYON, France, March 14, 2025--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial infections, announces the launch of a bidding process (appel d'offres) until April 11, 2025. The court-appointed administrator (administrateur judiciaire) has published a notice in the newspaper Les Echos (to be published on March 14, 2025) with a view to seeking potential buyers as part of a disposal plan (plan de cession). Interested parties wishing to respond to the call for tenders are invited to express their interest before April 11, 2025 at 12:00 am (CET) to: Maître Joanna Rousselet – Administrateur Update on the publication of the annual financial results and cash runway On March 6, 2025, the Commercial Court of Lyon ordered the opening of receivership proceedings (redressement judiciaire) and will decide on the extension of the procedure on April 30, 2025. In this context, the Company will not be in a position to publish its financial results for the financial year ending December 31, 2024 before April 30, 2025. In connection with this procedure, the Company believes it will be able to fund its operations until June 2025, after which date the Company will be liquidated. Resumption of trading of Phaxiam Therapeutics shares Phaxiam announces that the trading of its shares on Euronext Paris will resume on March 17, 2025, at market opening. Press releases will be published regularly as the procedure moves forward. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit View source version on Contacts PHAXIAM Thibaut du Fayet CEO+33 4 78 74 44 38investors@ NewCapMathilde Bohin / Dušan Orešanský Investor RelationsArthur RouilléMedia Relations+33 1 44 71 94 94phaxiam@ Sign in to access your portfolio
